Fluvoxamine & COVID: A Potential Outpatient Option

I always like to clarify that I am an ICU physician and not an outpatient physician. I personally have never written for fluvoxamine in my career and have never provided it to a COVID patient. That being said, I feel much of the help we need regarding therapies for COVID are to prevent these folks from deteriorating to the point where they need to meet me in the ICU. Many times these patients are too far gone when they arrive to the ICU for any meaningful turnaround. This article was published two days ago (11/12/20) in JAMA. Please read the article for yourself as it is free and don’t trust me.

Addendum on 10/28/21

Yesterday, 10/27/21, almost an entire year after the publication of the first paper cited in the above paragraph in JAMA, we received a positive update on the use of fluvoxamine in the outpatient setting for COVID-19. This is an update to this original webpage because I try to keep you all as current as possible and allow you to see what my previous thoughts were. From a personal standpoint, I feel somewhat vindicated that this is a positive study. After all, when I published my thoughts (available for you to listen to on my podcast as well as youtube channel) last year, my video was demonetized because YouTube felt that those data at the time was misinformation. Even though I titled it “A Potential Treatment”. Despite me challenging it, it is still demonetized. Some people have commented to me that I’ve become too dramatic but it’s all to illustrate that voices are being silenced if you go against the narrative. I say that as one of the first people who got vaccinated. That’s enough about that. Let’s get into the article.

My Short/Reel on YouTube.

Citations for Fluvoxamine in COVID

Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020 Nov 12. doi: 10.1001/jama.2020.22760. Epub ahead of print. PMID: 33180097.
Link to Article and FULL FREE PDF

Reis G dos Santos Moreira-Silva EA Medeiros-Silva DC et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.Lancet Glob Health. 2021; (published online Oct 27.)https://doi.org/10.1016/S2214-109X(21)00448-4
Link to Article

Link to Podcast and YouTube video on Fluvoxamine and COVID

Script for short/reel/etc.

  • We now have an additional tool for outpatient COVID-19!
  • Fluvoxamine has been shown to decrease the risk of hospitalization from COVID-19
  • This study was published on 10/27/21 in Lancet Global Medicine
  • Hat tip to the authors out of Brazil! Read the article for yourself and don’t trust me. I can’t do it all in one minute.
  • This was a placebo-controlled randomized trial in high-risk patients
  • By high-risk they mean diabetes, hypertension, cardiovascular disease, asthma, tobacco use, obesity, history of transplant, CKD or ESRD, unvaccinated, chemotherapy, etc.
  • They started therapy EARLY, within 7 days of symptom onset
  • Patients were given 100mg of fluvoxamine or placebo twice a day for 10 days.
  • Fluvoxamine is said to have anti-inflammatory, anti-viral, and anti-platelet properties. May also increase the plasma levels of melatonin.
  • Approximately 750 patients in each arm.
  • 11% of the fluvoxamine group reached the primary endpoint vs. 16% in the control group
  • This means the NNT to keep a person out of the ER is 20 in high-risk patients
  • This correlates to a 32% relative risk reduction.
  • There were no differences in adverse effects.
  • At approximately $4 per regimen, do you think we should put this in the water?

Although great care has been taken to ensure that the information in this post is accurate, eddyjoe, LLC shall not be held responsible or in any way liable for the continued accuracy of the information, or for any errors, omissions or inaccuracies, or for any consequences arising therefrom. For more articles on COVID-19 CLICK HERE.

How to support my work: my efforts are at no cost to you and I would like to keep it that way. You have to look at ads on this website, listen to them on my podcast and YouTube content. Thanks for bearing with me. You could also support my work by clicking on my Amazon Affiliate links prior to ordering things off of Amazon.

For example, if you want to learn more about Mechanical Ventilation, I recommend starting off with The Ventilator Book by Will Owens. If you click on that link, a window for Amazon will open up and I will earn between a 1-3% commission at no expense to you. The fun thing is that if you order anything else on Amazon, I will earn that amount off of your shopping cart even if you do not purchase the book. Pretty cool, right? In 2020, Amazon Affiliates helped me pay for the hosting of my website, LLC fees, and Netflix.

Another way that you can help is by signing up for a FREE trial for Audible by clicking HERE (www.audibletrial.com/5bZkZo). If you sign up for a free trial, I will be compensated $15. How’s that for transparency? Not to mention that I personally use Audible and enjoy it so it’s not challenging for me to promote it. You can also cancel your subscription before they bill your credit card if you’re not happy. You will get a free book with your promotion or two free books if you have a Prime membership. Thanks!

fluvoxamine covid